Breast cancer screening reimagined

An AI-powered RNA-based liquid biopsy for high-accuracy, early breast cancer detection.

Join Early Access Clinician Enrollment

LiquidMammo is being developed as a CLIA Laboratory Developed Test (LDT); it is not yet FDA‑cleared or FDA‑approved.

Dense breasts challenge mammography

Dense tissue can hide cancers on imaging, reducing sensitivity and increasing uncertainty.

Earlier biological signal

RNA changes may appear before tumors become visible on imaging.

More consistent screening

A biological complement helps improve confidence across diverse patient groups.

Clinical context

  • Mammograms have limitations, especially in dense breasts.
  • Dense tissue can obscure early cancers on imaging.
  • False positives are common and may lead to follow‑up imaging.
  • In very dense tissue, mammogram sensitivity can fall to ~61%.
  • Younger women tend to have denser breasts, making detection harder.
  • Screening performance varies with density, age, and equipment.

LiquidMammo is designed to support—not replace—imaging. Adding a biological signal gives clinicians an additional layer of insight to strengthen early detection.

How it works

1 — Ordered by clinician

A routine blood draw performed at a clinic or partner site.

2 — RNA profiling

A multi‑marker RNA panel is analyzed for meaningful biological patterns.

3 — Clinician‑ready report

Results include density‑aware interpretation and screening guidance.